 Why Lower Drug Prices Benefit Institutional Investors: an application of universal ownership theorySteve Lippman, Daniel E. Rosan and Adam Seitchik Corporate Governance: An International Review, 2007, vol. 15, issue 3, 455-466 Abstract: Changes in prescription drug prices have broad ripple effects across the diverse portfolios that most institutional investors hold. Lower prices cut into pharmaceutical company profits, but improve the overall productivity and profitability of other investable sectors of the economy. This paper considers the net impact of cuts in drug prices on investor portfolios. We find that falls in pharmaceutical company profits resulting from price cuts would be largely if not fully offset by a combination of health plan cost‐savings and increases in consumer spending power. Furthermore, falling drug prices benefit investors through the dynamic benefits from a healthier workforce with greater access to prescription drugs. We conclude that, from the perspective of the broadly diversified “universal investor”, support for lower drug prices is consistent with a fiduciary duty to seek attractive long‐term returns at the portfolio level. Strategies for shareholder activism should be expanded, including engagement with corporate health care purchasers and advocacy for public policy reform. Date: 2007 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:bla:corgov:v:15:y:2007:i:3:p:455-466 Ordering information: This journal article can be ordered from Access Statistics for this article Corporate Governance: An International Review is currently edited by William Judge More articles in Corporate Governance: An International Review from Wiley Blackwell |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.